Welcome to our dedicated page for Grifois news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifois stock.
Grifols, S.A. reports developments tied to its global healthcare business, including plasma-derived medicines, diagnostic technologies, transfusion-medicine solutions and biological supplies for research, clinical trials and pharmaceutical or diagnostic manufacturing. Its business references include Biopharma, Diagnostic, Bio Supplies and other activities such as manufacturing services, research and complementary pharmaceutical products.
Recurring news themes include product and regulatory updates for plasma-protein therapies, such as fibrin sealant for surgical bleeding, and research programs that use plasma assets, AI, proteomics and real-world data. Coverage also includes Chronos-PD work led by Alkahest, shareholder communications on board composition and disclosure, and capital-market topics affecting Grifols' listed shares in Spain and the United States.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Grifols, a global healthcare company specializing in plasma-derived medicines, announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the SEC on April 18, 2023. This filing emphasizes the company's commitment to transparency, providing insights into governance, risk management, and financial performance. The report includes audited financial statements in compliance with IFRS, management's discussion and analysis (MD&A), and key performance indicators. Additionally, Grifols addressed a deficiency letter from Nasdaq regarding audit committee compliance, which was resolved with the appointment of a new member. Grifols shares are listed on the Spanish stock market and NASDAQ, with significant economic impacts reported in its operational regions.